form8k.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
January
15, 2010
(Date of
report)
CARACO
PHARMACEUTICAL LABORATORIES, LTD.
(Exact
name of registrant as specified in its charter)
Michigan
|
|
1-31773
|
|
38-2505723
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
file number)
|
|
(I.R.S.
employer identification no.)
|
1150 Elijah McCoy Drive,
Detroit, Michigan 48202
(Address
of principal executive offices)
(313)
871-8400
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
140.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
1.01. Entry into a Material Definitive Agreement
On
January 15, 2010, Caraco Pharmaceutical Laboratories, Ltd. (“Caraco”
or the “Company”) and Sun Pharmaceutical Industries Limited (“Sun Pharma”)
entered into an amendment of the marketing agreement they originally entered
into on January 19, 2007. The amendment simply extends the term of
the agreement for an additional year to January 19, 2011. As
previously disclosed, under such agreement, Sun may offer certain products which
require ANDAs to Caraco, and if Caraco agrees to such offer, it will purchase
such products for marketing to new and existing
customers. The amendment was approved by Caraco’s Independent
Committee (comprised of three independent directors).
The
foregoing summary of the marketing agreement is qualified in its entirety by
reference to the marketing agreement filed as Exhibit 10.20 to that certain
Amendment No. 1 to Form 8-K filed with the Securities and Exchange Commission on
November 5, 2007. The Company redacted certain portions
of such Exhibit 10.20 pursuant to an FOIA Confidential Treatment Request
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as
amended. On January 18, 2010, pursuant to Rule 24b-2, the Company
sent by overnight delivery an application to the Secretary of the Commission
requesting an extension of such confidential treatment pursunt
to an FOIA Confidential Treatment Request. The omitted
material is included in the application for extension of such confidential
treatment.
Item
9.01. Financial Statements and Exhibits
10.33
|
First
Amendment to Agreement Between Caraco Pharmaceutical Laboratories, Ltd.
and Sun Pharmaceutical Industries Limited dated January 15,
2010.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
CARACO
PHARMACEUTICAL LABORATORIES, LTD.
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
Date: January
21, 2010
|
|
By:
|
/s/
Jitendra N. Doshi
|
|
|
|
|
Jitendra
N. Doshi
|
|
|
|
|
Chief
Executive Officer
|
|
Exhibit
Index
|
First
Amendment to Agreement Between Caraco Pharmaceutical Laboratories, Ltd.
and Sun Pharmaceutical Industries Limited dated January 15,
2010
|
2